Next, PRJEB25780 cohort (PD-L1 inhibitor treatment for 45 patients with advanced gastric cancer [29]) was applied to validate whether the mitochondrial-related risk signature could accurately predict the responses to immunotherapy for patients with STAD. This evidence concerns the gene CD274 and gastric adenocarcinoma.